Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35604212/
doi: 10.1128/aac.00215-22. Online ahead of print. 1 Division of Clinical Pharmacology, Department of Medicine, University of Cape Towngrid.7836.a, Cape Town, South Africa. 2 Division of Clinical Pharmacology, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA. 3 Centre for Tuberculosis Research, Johns Hopkins University School of Medicinegrid.471401.7, Baltimore, Maryland, USA.
Conclusion: Although 50 mg of dolutegravir given twice daily achieves target concentrations in more than 99% of individuals cotreated with rifampicin, 100 mg of dolutegravir, once daily, in the same population is predicted to achieve satisfactory pharmacokinetic target attainment. The efficacy of this regimen should be investigated since it presents an opportunity for treatment simplification.